Vigil Neuroscience to Present at Upcoming Investor Conferences
Nov 12, 2024
|
PDF Version
Read More
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov 07, 2024
|
PDF Version
Read More
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference
Nov 05, 2024
|
PDF Version
Read More
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
Sep 17, 2024
|
PDF Version
Read More
Vigil Neuroscience to Present at Cantor Global Healthcare Conference
Sep 16, 2024
|
PDF Version
Read More
Vigil Neuroscience to Present at Upcoming September Investor Conferences
Aug 29, 2024
|
PDF Version
Read More
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
Aug 13, 2024
|
PDF Version
Read More
Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics
Aug 01, 2024
|
PDF Version
Read More
Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)  
Jul 30, 2024
|
PDF Version
Read More
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
Jul 24, 2024
|
PDF Version
Read More
Displaying 1 - 10 of 25
Print Page
Print Page
Email Alerts
Email Alerts
RSS Feeds
RSS Feeds
Contact IR
Contact IR

Exit

You are leaving Vigil Neuroscience, Inc.’s website. You may return to Vigil Neuroscience, Inc.’s website by using the “Back” button on your Web browser toolbar or closing the window to the third-party website that you have opened. Do you wish to continue?

 

Yes
No